Neogen Corporation Debt Securities, Trading, Unrealized Loss
Neogen Corporation (NEOG) reported Debt Securities, Trading, Unrealized Loss of $2.97 million for the 12-month period ending 2022-05-31, per its 10-K filed 2022-07-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DebtSecuritiesTradingUnrealizedLoss · last filed 2022-07-27
- Neogen Corporation debt securities, trading, unrealized loss for the quarter ending 2022-05-31 was $1.11M.
- Neogen Corporation debt securities, trading, unrealized loss for the quarter ending 2022-02-28 was $1.16M, a 1032.35% increase year-over-year.
- Neogen Corporation debt securities, trading, unrealized loss for the quarter ending 2021-11-30 was $578.00K, a 514.89% increase year-over-year.
- Neogen Corporation debt securities, trading, unrealized loss for the quarter ending 2021-08-31 was $123.00K, a 115.79% increase year-over-year.
- Neogen Corporation debt securities, trading, unrealized loss for fiscal 2022 was $2.97M, a 8896.97% increase from fiscal 2021.
- Neogen Corporation debt securities, trading, unrealized loss for fiscal 2021 was $33.00K, a 43.48% increase from fiscal 2020.
- Neogen Corporation debt securities, trading, unrealized loss for fiscal 2020 was $23.00K.
| Period end | Debt Securities, Trading, Unrealized Loss 3 month | Debt Securities, Trading, Unrealized Loss 6 month | Debt Securities, Trading, Unrealized Loss 9 month | Debt Securities, Trading, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2022-05-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-27 | $2.27M derived: sum of 2 quarters · filed 2022-07-27 | $2.85M derived: sum of 3 quarters · filed 2022-07-27 | $2.97M 10-K · filed 2022-07-27 |
| 2022-02-28 | $1.16M derived: 10-K 12 month − 3 quarters · filed 2022-07-27 | $1.73M derived: sum of 2 quarters · filed 2022-07-27 | $1.86M 10-Q · filed 2022-04-01 | $1.64M derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-11-30 | $578.00K 10-Q · filed 2021-12-30 | $701.00K derived: sum of 2 quarters · filed 2021-12-30 | $481.00K derived: sum of 3 quarters · filed 2022-07-27 | $583.00K derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-08-31 | $123.00K 10-Q · filed 2021-09-30 | -$97.00K derived: sum of 2 quarters · filed 2022-07-27 | $5.00K derived: sum of 3 quarters · filed 2022-07-27 | $99.00K derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-05-31 | -$220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-27 | -$118.00K derived: sum of 2 quarters · filed 2022-07-27 | -$24.00K derived: sum of 3 quarters · filed 2022-07-27 | $33.00K 10-K · filed 2022-07-27 |
| 2021-02-28 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-03-31 | $196.00K derived: sum of 2 quarters · filed 2021-03-31 | $253.00K 10-Q · filed 2021-03-31 | |
| 2020-11-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-12-29 | $151.00K 10-Q · filed 2020-12-29 | ||
| 2020-08-31 | $57.00K 10-Q · filed 2020-09-30 | |||
| 2020-05-31 | $23.00K 10-K · filed 2021-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |